Abstract
Acute myeloid leukemia (AML) is a highly aggressive disease with high relapse and mortality rates. Recent years have shown a surge in novel therapeutic development for AML, both in clinical and preclinical stages. These developments include targeted therapies based on AML-specific molecular signatures as well as more general immune modulation and vaccination studies. In this review, we will explore the evolving arena of AML therapy and suggest some intriguing connections between immune system modulation and targeted therapy. Improved understanding of the immune system involvement in various stages of the disease and the crosstalk between immune effectors, targeted therapy, and AML cells can provide a better framework for designing the next generation of AML therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 34-43 |
| Number of pages | 10 |
| Journal | European Journal of Immunology |
| Volume | 52 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
Bibliographical note
Funding Information:Research work in the authors' laboratory are supported by the Israel Science Foundation (ISF)?Centers of Excellence, ISF Grant 3165/19 within the Israel Precision Medicine Program, the Joseph Lebovic charitable Foundation, the European Research Council (883552-ONCODESTROYER), and the Israel Cancer Research Fund Professorship.
Funding Information:
Research work in the authors' laboratory are supported by the Israel Science Foundation (ISF)—Centers of Excellence, ISF Grant 3165/19 within the Israel Precision Medicine Program, the Joseph Lebovic charitable Foundation, the European Research Council (883552‐ONCODESTROYER), and the Israel Cancer Research Fund Professorship.
Publisher Copyright:
© 2021 Wiley-VCH GmbH
Keywords
- Humans
- Leukemia, Myeloid, Acute/genetics
- Molecular Targeted Therapy
